...
首页> 外文期刊>Seminars in pediatric neurology >Genotype/Phenotype Correlations in Tuberous Sclerosis Complex
【24h】

Genotype/Phenotype Correlations in Tuberous Sclerosis Complex

机译:结节性硬化症基因型/表型的相关性

获取原文
获取原文并翻译 | 示例

摘要

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterized by the development of widespread hamartomatous lesions in various organs, including brain, skin, kidneys, heart, and eyes. Central nervous system is almost invariably involved, with up to 85% of patients presenting with epilepsy, and at least half of patients having intellectual disability or other neuropsychiatric disorders including autism spectrum disorder. TSC is caused by the mutation in one of the 2 genes TSC1, at 9q34, and TSC2, at 16p13.3. They respectively encode for hamartin and tuberin, which form an intracellular complex inhibiting the mammalian target of rapamycin. Mammalian target of rapamycin overactivation following the genetic defect determines the cell growth and proliferation responsible for TSC-related lesions, as well as the alterations in neuronal excitability and synaptogenesis leading to epilepsy and neuropsychiatric disorders. A causative mutation for the disorder is identified in about 85% of patients with a clinical diagnosis of TSC. Mosaicism and technology limits likely explain most of the no mutation identified cases. This review confirms that patients with TSC2 mutations considered as a group usually present a more severe phenotype, characterized by higher number of tubers, earlier age at seizure onset and higher prevalence of intellectual disability. However, the clinical phenotype of the disease presents a high variability, thus making the prediction of the phenotype on an individual basis still challenging. The increasing application of new molecular techniques to subjects with TSC has the potential to significantly reduce the rate of patients with no mutation demonstrated and to identify an increasing higher number of mutations. This would hopefully allow a better characterization of higher risk mutations, which might help clinicians to plan individualized surveillance plans. Furthermore, the increasing availability of disease registries to collect clinical and genetics data of patients help to define more valid and clinically oriented genotype or phenotype correlations. (C) 2015 Elsevier Inc. All rights reserved.
机译:结节性硬化症(TSC)是常染色体显性遗传疾病,其特征是在各个器官(包括脑,皮肤,肾脏,心脏和眼睛)中出现了广泛的错构瘤性病变。中枢神经系统几乎总是被累及,多达85%的患者患有癫痫病,至少一半的患者患有智力障碍或其他神经精神疾病,包括自闭症谱系障碍。 TSC是由两个基因之一TSC1(位于9q34)和TSC2(位于16p13.3)中的突变引起的。它们分别编码形成martin和哺乳动物雷帕霉素靶标的细胞内复合物的martin和tuberin。遗传缺陷后雷帕霉素过度活化的哺乳动物靶标决定了与TSC相关损伤有关的细胞生长和增殖,以及导致癫痫和神经精神疾病的神经元兴奋性和突触发生改变。在临床诊断为TSC的约85%的患者中鉴定出该疾病的病因突变。马赛克和技术限制很可能解释了大多数未发现突变的情况。该评价证实具有TSC2突变的患者通常被认为具有更严重的表型,其特征在于块茎数量更多,发作发作的年龄更早以及智力残疾的患病率更高。然而,该疾病的临床表型呈现出高变异性,因此使得基于个体的表型预测仍然具有挑战性。新分子技术在TSC患者中的日益增加的应用潜力有可能显着降低未证实突变的患者的发病率,并确定越来越多的突变。希望这可以更好地表征较高风险的突变,这可能有助于临床医生制定个性化的监测计划。此外,收集患者临床和遗传数据的疾病登记簿的可用性不断提高,有助于定义更有效和临床导向的基因型或表型相关性。 (C)2015 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号